Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have used a death-record search to define the frequency of lethal outcomes of hepatitis B virus infection among a population of more than 15,000 overtly healthy blood donors found positive in routine HBsAg testing. We have compared the study population with a control group of some 18,000 donors selected on the basis of a negative test result. The index and control groups were observed for periods reflecting a total of 55 and 59 thousand person-years, respectively. Twenty percent of the 134 deaths identified among HBsAg positive donors were in some way liver related, including seven deaths due to hepatitis, seven to cirrhosis and six to hepatoma. In contrast, only one of the 95 deaths in the control population was liver related, and was due to fatty degeneration of the liver. The majority (four) of the hepatoma deaths occurred among blacks, three of whom were less than 35 at the time of death. In contrast, deaths from cirrhosis were all among whites. We conclude that there is significant mortality associated with the HBsAg positive state, even though the affected individuals may be asymptomatic and well enough to give blood at some stage. We estimate the standardised mortality ratio for hepatoma among HBsAg-positive persons in the United States is at least 27, confirming the association observed in other populations. The risk for hepatoma among young, HBsAg positive black males appears to approach that reported for HBsAg positive males in Taiwan. Data on the feasibility of AFP testing for early detection of hepatoma are included and discussed.
 ...
PMID:Increased risk for lethal forms of liver disease among HBsAg-positive blood donors in the United States. 244 15

Primary liver carcinoma (PLC) may express a certain number of markers. Here we communicate results of an analysis of five such markers (alpha-1-antitrypsin--AAT--, carcino-embryonic antigen --CEA--, alpha-fetoprotein --AFP--, and superficial --HBsAg-- and core --HBcAg-- antigens of hepatitis B virus) by means of PAP techniques in 130 cases of PLC, comparing the neoplastic tissue and the non-tumorous liver. Three variants of PLC are distinguished: hepatocarcinoma (HC) (108 cases); cholangiocarcinoma (CC) (19 cases); and three cases of hepatocholangiocarcinoma (HCC). AAT was positive in 29 HC, 2 HCC, and negative in all 19 CC. CEA appeared positive in 16 HC, 16 CC and only one HCC. AFP was positive in two HC, and negative in all CC and HCC. HBsAg displayed positivity in 15 HC and one HCC, being negative in all 19 CC. HBcAg was positive in 4 HC, and negative in all CC and HCC. HBsAg was also positive in two neoplastic emboli associated with HC. On the non-tumorous liver tissue the immunohistochemical results showed positivity for AAT and CEA, but not for AFP. Therefore the present results confirm that in the geographical area from which these tumors proceed, PLC is closely correlated with HBsAg positivity and with cirrhosis.
 ...
PMID:Immunohistochemical characterization of 130 cases of primary hepatic carcinomas. 244 80

Hepatocellular carcinoma (HCC) is a rapidly fatal neoplasm of high worldwide prevalence. Fibromellar carcinoma (FLC), a variant of HCC, lacks the dismal prognosis of "ordinary" HCC (O-HCC) and is characterized by a diagnostic histologic appearance. The current study analyzes the clinical characteristics, immunohistochemistry, and treatment of nineteen cases of FLC. These data, together with a detailed review of the literature, further characterize this unique variant. FLC affects younger patients and lacks the male predominance of O-HCC. Also, FLC lacks specific association with cirrhosis, hepatitis B virus infection, use of oral contraceptives, and alcohol abuse, all of which are implicated in other hepatic tumors. This, along with differences in serum tumor marker prevalence (AFP, B12 binding protein) suggests that its pathogenesis differs from that of O-HCC. Despite these differences, FLC shares a common differentiation with O-HCC. The increased amounts in FLC of stainable alpha-1-antitrypsin, fibrinogen, and C-reactive protein, all of which are acute phase reactants and normal hepatocyte products, implies better differentiation of FLC cells. Finally, the better prognosis of FLC is supported by this study, since only two of the 19 patients died because of tumor. This contrasts with the reported survival of patients with O-HCC, usually measured in weeks. Hepatic transplantation may hold promise for future patients with "surgically unresectable" FLC as procedure-related complications are overcome.
 ...
PMID:Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. 245 77

All the cases of proven hepatocellular carcinoma seen at Westmead Hospital, Sydney between January 1980 and the end of 1987 were reviewed. Hepatitis B infection was the major predisposing condition. Six patients had taken significant doses of sex steroids. Seventeen of the patients were cirrhotic at the time of diagnosis and in seven of these there was a significant history of alcohol abuse. AFP was elevated in only 15 of the 34 patients. Multiple regression analysis revealed that the single, independent determinant of a raised AFP level was found to be presence of Hepatitis B infection. Resection was possible in 10 patients. In the last ten months, seven patients have been treated by embolisation of the tumour with Adriamycin bonded to lipidol. Survival was influenced by the presence or absence of cirrhosis but not by evidence of Hepatitis B infection. The prognosis for patients with hepatocellular carcinoma in Australia is as dismal as it is in any other country. Although a rare tumour its incidence may well increase as the community now contains relatively greater numbers of immigrants from areas where the risk of developing a hepatocellular carcinoma is higher and because of the number of drug addicts who are frequently exposed to Hepatitis B infection. With the exception of patients with Hepatitis B infection, screening with AFP holds little promise in the Caucasian community.
 ...
PMID:Hepatocellular carcinoma in western Sydney. 246 Nov 43

Two hundred ninety patients (203 men, 87 women), age 7 to 74 years (mean: 39.1 years), with chronic hepatitis B virus infection, were prospectively followed for a period of 1 to 4 years to determine the value of alpha-fetoprotein monitoring in the early detection of hepatocellular carcinoma. At presentation, 66% of the patients were asymptomatic, 19% had chronic hepatitis and 15% had established cirrhosis. Forty-four (15%) patients had elevated alpha-fetoprotein levels on one or more occasions during the study period. Twenty patients with normal alpha-fetoprotein levels at presentation developed elevated alpha-fetoprotein levels during the course of follow-up, whereas 24 patients had elevated alpha-fetoprotein levels at presentation. Six (14%) of these 44 patients (five men and one woman), age 23 to 66 years, had persistent or progressive increase in alpha-fetoprotein levels and were confirmed to have hepatocellular carcinoma. In four patients, the alpha-fetoprotein levels were below 500 ng per ml at the time of tumor localization. Only three patients had resectable tumors. All six patients would have been missed if alpha-fetoprotein screening was restricted to men above the age of 40 with cirrhosis and anti-HBe. Of the remaining 38 patients, elevation in alpha-fetoprotein levels in 18 patients was associated with exacerbations of the underlying liver disease and/or significant changes in level of hepatitis B virus replication, but in 20 patients, no apparent cause could be identified. The elevation in AFP levels exceeded 200 ng per ml in 26% and persisted beyond 6 months in 15% of these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. 247 84

Two hundred and eighty-two patients with HCC including 89 with tumors 2 cm or smaller in size and 193 of 2-5 cm were studied on clinical and pathological findings and correlated with the value of various diagnostic imaging modalities. There were apparent differences in histological findings of HCC between 2 cm or smaller in size and larger ones; the former had much less invasion of malignant cells to the extracapsule and portal vein neighbouring the HCC than the latter. In 83 patients with HCCs 2 cm or less in diameter AFP level was normal (less than 20 ng/ml) in 39.8%, 20-200 ng/ml in 44.6% and more than 200 ng/ml in only 15.6%. Detectability of HCC measuring 2 cm or less by various imaging modalities was as follows: 97.8% by US, 54% by X-ray computed tomography (CT), 61.6% by magnetic resonance imaging (MR) and 75.4% by angiography. There was considerable limitation of imaging modalities in making a definitive diagnosis of the smaller HCCs, particularly in the differentiation from regenerative nodules of liver cirrhosis. Tissue biopsy under ultrasound control provided a correct diagnosis in 36 out of 41 patients (87.8%) with HCCs 2 cm or less in size, a better ratio than for aspiration biopsy.
 ...
PMID:Strategy for early diagnosis of hepatocellular carcinoma (HCC). 246 79

HBsAg, HBcAg and AFP in small liver cancer (less than or equal to 5 cm) and adjacent non-neoplastic liver tissue were assayed by peroxidase-antiperoxidase (PAP) method. The positive rates of HBsAg, HBcAg and AFP in liver cancer tissue were 13.8% (9/65), 9.2% (6/65) and 75.0% (42/56), while those in the uninvolved liver tissue were 93.3% (97/104), 46.2% (48/104), 66.1% (37/56), respectively. 3.6% (2/56) of cancer tissue and 33.9% (19/56) of unaffected liver tissue were found to have these three markers simultaneously. Pathologically all showed chronic hepatitis changes, and 66.3% (69/104) of them had cirrhosis. The development of liver cancer may be associated with HBV/DNA integration, but it does not rule out the possibility of HBV replication in the canceration. The phenotype patterns of HBAg possess variable clinical significance and HBV replication affects the long time survival of the patients with liver cancer. The results show that both cancer foci and their surrounding tissue could secrete AFP, and the AFP positive rate in liver cancer with negative sero-AFP is 30% (3/10). The sensitivity of assaying HBsAg in PAP method was 1.4 times as high as that of R-PHA or orcein stain. Small liver cancer is a valuable material to the study of human liver cancer.
 ...
PMID:[Immunohistochemical study on HBsAg, HBcAg and AFP in 104 patients with small liver cancer]. 247 May 64

Plasma abnormal prothrombin (protein induced by vitamin K absence or antagonist-II: PIVKA-II) was evaluated as a serological marker for hepatocellular carcinoma (HCC). Its plasma levels were measured by enzyme immunoassay using an anti-PIVKA-II monoclonal antibody in 1010 patients with various diseases. Of 192 patients with HCC, 116 (60%) had abnormal PIVKA-II levels greater than 0.1 AU/ml. Elevation of PIVAK-II levels was observed rarely in chronic hepatitis, liver cirrhosis and other malignant tumors. Plasma PIVKA-II levels in HCC increased with tumor size. Normal levels were observed in patients with tumors measuring 2 cm or less in diameter. As a result, diagnostic application of plasma PIVKA-II levels to small liver tumors is limited. The sensitivity of PIVKA-II in the diagnosis and monitoring of HCC was increased by serial and simultaneous determinations of AFP, because high PIVKA-II levels were observed more often in low AFP-producing HCC patients. In some patients with HCC, plasma PIVKA-II levels decreased after surgical resection of the tumor or chemoembolization with cisplatin suspended in Lipiodol (LPS), but later rose again with recurrence of the disease. Elevated plasma PIVKA-II levels were not related to low vitamin K concentration in the serum. In fact, in many patients vitamin K administration resulted in only a moderate reduction of PIVKA-II levels. From these results, plasma PIVKA-II assay by the EIA method using a monoclonal antibody is a useful tool for the diagnosis and monitoring of HCC, particularly in HCC patients with low AFP levels.
 ...
PMID:[Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma]. 247 53

The relationship between hepatitis B virus (HBV) infection and cirrhosis (CIR) and hepatocellular carcinoma (HCC) was investigated. 340 cases with HCC and 99 cases with CIR were compared with the control group which were asymoptomatic age- and sex-matched case. Both HCC and CIR have higher infection rated of HBV and the positivity rated of HBsAg than their controls in both sexes. The positivity rate (74.8%) of HBsAg in HCC is significantly higher than that (58.2%) in CIR. HBeAg is more frequently positive in CIR than in HCC, especially among females. There was no sex difference in HBsAg positive among HCC nor among CIR. Age-adjusted AFP elevation is significantly more frequent in HBsAg-positive HCC than in HBsAg-negative. Both HCC and CIR in the Philippines are closely associated with HBV infection. The association with the infection is stronger with HCC than with CIR. Other causative/contributary factors may be important, especially with CIR. However, the great majority of HCC are probably due to chronic HBV infection, the public health control of which may result in a significant diminution of the malignancy in the country.
 ...
PMID:The relationship of hepatocellular carcinoma and liver cirrhosis to hepatitis B virus infection in the Philippines. 247 58

Serum alpha-L-fucosidase (AFU) was determined in 33 patients with hepatocellular carcinoma (HCC), 4 with secondary metastatic liver cancer, 61 with various liver diseases, 12 with gastrointestinal tumor and 50 healthy controls. The results showed that AFU level was significantly higher in HCC (14.48 +/- 5.77) than that in the controls (3.33 +/- 0.72) and in patient with other diseases (P less than 0.01). Serum AFU level was also increased in fulminant hepatitis (8.96 +/- 3.99), acute hepatitis (8.94 +/- 4.94) and chronic hepatitis (7.27 +/- 2.58), P less than 0.01 or 0.05. There was no significant difference in AFU level between the controls and patients with secondary metastatic liver cancer (6.25 +/- 0.84), cirrhosis (6.30 +/- 3.17), gastrointestinal tumor (4.43 +/- 1.64), liver hemangioma and liver abscess (4.86 +/- 2.22). A level exceeding 10.5u was a useful marker for the diagnosis of HCC with 78.8% sensitivity and 90.0% specificity. The diagnostic positivity was 81.8% in low AFP producing HCC, whereas 93.9% in those with elevated AFP. Our data indicate that serum AFU is a useful tumor marker for HCC, particularly in detection of AFP-low or negative HCC patients.
 ...
PMID:[A preliminary study on serum alpha-L-fucosidase assay in the diagnosis of hepatocellular carcinoma]. 248 Feb 10


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>